rss
Ann Rheum Dis 66:880-885 doi:10.1136/ard.2006.067660
  • Extended report

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

  1. Loreto Carmona1,
  2. Miguel Ángel Descalzo1,
  3. Eva Perez-Pampin2,
  4. Dolores Ruiz-Montesinos3,
  5. Alba Erra4,
  6. Tatiana Cobo5,
  7. Juan J Gómez-Reino2,
  8. on behalf of the BIOBADASER and EMECAR Groups*
  1. 1Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
  2. 2Rheumatology Service, Department of Medicine, Hospital Clinico Universitario, Medical School, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
  3. 3Rheumatology Service, Hospital Virgen Macarena, Sevilla, Spain
  4. 4Rheumatology Service, Hospital Vall d’Hebron, Barcelona, Spain
  5. 5Rheumatology Service, Hospital La Paz, Madrid, Spain
  1. Correspondence to:
    Dr J J Gómez-Reino
    Rheumatology Service, Department of Medicine, Hospital Clínico Universitário, A Choupana s/n, 15706 Santiago, Spain; juan.gomez-reino.carnota{at}sergas.es
  • Accepted 19 February 2007
  • Published Online First 26 February 2007

Abstract

Background: Mortality is increased in rheumatoid arthritis (RA), mainly because of cardiovascular (CV) events, cancer and infections. Recent data suggest that treatment with tumour necrosis factor (TNF) antagonists may affect this trend.

Objective: To assess whether treatment with TNF antagonists is associated with reduction in CV events, cancer and infection rates, and in mortality in patients with RA treated and not treated with TNF antagonists.

Methods: BIOBADASER is a registry for active long-term follow-up of safety of biological treatments in patients with RA. It includes 4459 patients with RA treated with TNF antagonists. EMECAR is an external RA cohort (n = 789) established to define the characteristics of the disease in Spain and to assess comorbidity. The incidence density (ischaemic heart disease) of CV events, cancer and infections was estimated and compared. The standardised mortality ratio was compared with the rate in the general population. A propensity score was used to match cohorts by the probability of being treated.

Results: Rates of CV and cancer events are significantly higher in EMECAR than in BIOBADASER (RR 5–7 for different CV events, and RR 2.9 for cancer), whereas the rate of serious infections is significantly higher in BIOBADASER (RR 1.6). Mortality ratio of BIOBADASER by EMECAR is 0.32 (0.20–0.53) for all causes of death, 0.58 (0.24–1.41) for CV events, 0.52 (0.21–1.29) for infection and 0.36 (0.10–1.30) for cancer-related deaths.

Conclusion: Morbidity, other than infection, and mortality are not higher than expected in patients with RA treated with TNF antagonists.

Footnotes

  • * Author list appears in the appendix.

  • Published Online First 23 February 2007

  • Competing interests: JJGR is on the Advisory Boards of Wyeth and Schering Plough, and has received lectures fees from Abbott, Wyeth, and Schering Plough.